Search clinical trials for: MK-0677

Total 1710 results

National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States, Canada
Merck Sharp & Dohme LLC

Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Invasive Aspergillosis

Belgium, United States, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Endometrial Neoplasms

France, Canada, United States, Spain, United Kingdom, Italy, Taiwan, Korea, Republic of, Colombia, Australia, New Zealand, Brazil, Turkey, Poland, Israel, Argentina, Germany, Ireland, Japan, Mexico, Russian Federation
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University

Terminated

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

Stage IV Lung Non-Small Cell Cancer AJCC v7 | Lung Carcinoma Metastatic in the Brain

United States
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) (reSURFACE 2)

Plaque Psoriasis
Merck Sharp & Dohme LLC

Terminated

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Overactive Bladder | Overactive Urinary Bladder
Garden State Infectious Disease Associates, PA
GlaxoSmithKline

Completed

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Healthy
University of North Carolina, Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

MK-0518 Intensification And HDAC Inhibition In Depletion Of Resting CD4+ T Cell HIV Infection

HIV Infections

United States
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Sezary Syndrome | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | T-Cell Prolymphocytic Leukemia | B-Cell Prolymphocytic Leukemia

United States
Floor Backes, MD

Active, not recruiting

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

Prophylaxis | Human Immunodeficiency Virus Type 1 | HIV-I

United States, South Africa, Uganda
NYU Langone Health

Completed

Carbidopa for the Treatment of Excessive Blood Pressure Variability (CarbiFD)

Dysautonomia, Familial | Baroreflex Failure Syndrome

United States
Onze Lieve Vrouw Hospital

Completed

Oral Anticoagulation in Hemodialysis

Atrial Fibrillation

Belgium
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive Aspergillosis

Invasive Aspergillosis | Invasive Candidiasis
Augusta University
Yale University; University of Alabama at Birmingham; Tufts University

Unknown

Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)

Obesity | Insulin Resistance | Insulin Sensitivity | Prediabetes | Beta-Cell Dysfunction

United States
China Medical University Hospital

Unknown

Psoriasis、Indigo Naturalis、Chinese Medicine Medicated Bath

Psoriasis

Taiwan
Merck Sharp & Dohme LLC

Completed

A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) (STOP CHAGAS)

Chagas Disease
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)

Fungal Infections
David A Wohl, MD
Merck Sharp & Dohme LLC

Completed

Raltegravir as Early Therapy in African-Americans Living With HIV Study (REAL)

HIV Infections

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Poland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

HIV-1 Infection

United States, Argentina, Canada, Chile, Colombia, France, Germany, Israel, Italy, Japan, South Africa, Spain, Taiwan
Nicholas Fidelman, MD
Merck Sharp & Dohme LLC; BTG International Inc.

Active, not recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Liver

United States
M.D. Anderson Cancer Center

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Lung Small Cell Carcinoma

United States
Organon and Co

Completed

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710) (Care)

Pregnancy | Neonates
Merck Sharp & Dohme LLC

Terminated

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Follicular Lymphoma
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Hematologic Diseases | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Withdrawn

FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Merck Sharp & Dohme LLC

Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Invasive Fungal Infection

Israel, United States, Belgium, Greece, Peru, Poland, Mexico, Russian Federation
Organon and Co

Terminated

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)

Contraception
Semnan University of Medical Sciences

Terminated

Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant

Polycystic Ovary Syndrome | Hyperandrogenism
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

Invasive Pulmonary Aspergillosis | Fungal Infections
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Metastatic Triple Negative Breast Cancer
Merck Sharp & Dohme LLC

Terminated

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Multiple Myeloma
Augusta University

Unknown

Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)

Hyperglycemia | Cardiovascular Diseases | Obesity | Insulin Resistance | Hyperlipidemia | Nutritional and Metabolic Diseases | Obesity in Diabetes

United States
Merck Sharp & Dohme LLC

Terminated

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030) (EVADE)

Nausea | Vomiting
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Withdrawn

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Hepatitis B
Roswell Park Cancer Institute

Not yet recruiting

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Unresectable Triple-Negative Breast Carcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Diffuse Large B-Cell Lymphoma | DLBCL

Poland, United States, France, Israel, Italy, Turkey, Canada, Korea, Republic of, United Kingdom, Thailand, China
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Kidney Cancer | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer

United States, Germany, Israel, Canada, China, Australia, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Russian Federation, Turkey and more
Oncoimmune, Inc., a subsidiary of Merck & Co.,...
National Cancer Institute (NCI); University of Michigan Rogel Cancer Center; Ohio... and other collaborators

Completed

Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)

Leukemia | Hematopoietic Stem Cell Transplantation | Graft Versus Host Disease

United States
Ashraf Badros
Merck Sharp & Dohme LLC

Terminated

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

Cervical Cancer

Japan, United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Mexico, Peru, Russian Federation, Spain, Taiwan, Turkey, Ukraine
University of Missouri-Columbia
Merck Sharp & Dohme LLC

Enrolling by invitation

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Spine Surgery | Urinary Retention Postoperative | Reversal of Neuromuscular Blockade

United States

Search clinical trials for: MK-0677

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations